^
Association details:
| Biomarker: | MEF2C overexpression |
|---|---|
| Cancer: | T Acute Lymphoblastic Leukemia |
| Drug: | ABT-737 (Bcl2 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
Excerpt:
Treatment with PSL and ABT-737 caused a significant reduction in the IC50 of PSL in the MEF2C-expressing LOUCY cells, in addition to the MEF2C-transduced BaF3 cells, but not in the non-MEF2C-expressing Jurkat cells. The combination treatment significantly accelerated the killing of primary leukemic blast cells of ETP-ALL with high expression levels of MEF2C, which were co-cultured with murine stromal cells.
Secondary therapy:
prednisolone
DOI:
10.1371/journal.pone.0132926
